Catalio Capital Management LP Invests $5.14 Million in BridgeBio Oncology Therapeutics, Inc $BBOT

Catalio Capital Management LP bought a new position in shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) during the fourth quarter, HoldingsChannel reports. The fund bought 410,700 shares of the company’s stock, valued at approximately $5,142,000.

A number of other hedge funds have also modified their holdings of BBOT. Geode Capital Management LLC grew its position in shares of BridgeBio Oncology Therapeutics by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock worth $7,039,000 after acquiring an additional 20,385 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth approximately $1,185,000. BIT Capital GmbH purchased a new position in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth approximately $313,000. CIBC Private Wealth Group LLC purchased a new position in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth approximately $63,000. Finally, Renaissance Technologies LLC purchased a new position in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth approximately $930,000. 54.89% of the stock is currently owned by hedge funds and other institutional investors.

BridgeBio Oncology Therapeutics Trading Down 0.6%

BridgeBio Oncology Therapeutics stock opened at $7.68 on Thursday. The stock has a market cap of $615.24 million, a PE ratio of -3.75 and a beta of 0.29. The stock’s 50-day moving average is $8.43. BridgeBio Oncology Therapeutics, Inc has a 52 week low of $7.00 and a 52 week high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($526.11) EPS for the quarter. Equities research analysts predict that BridgeBio Oncology Therapeutics, Inc will post -2.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BBOT. Canaccord Genuity Group began coverage on shares of BridgeBio Oncology Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $23.00 target price on the stock. HC Wainwright raised their target price on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Finally, Wall Street Zen lowered shares of BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $25.00.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.